Allovir, Inc. Files 2024 10-K, Reports Merger with Kalaris
Ticker: KLRS · Form: 10-K · Filed: Mar 7, 2025 · CIK: 1754068
| Field | Detail |
|---|---|
| Company | Allovir, Inc. (KLRS) |
| Form Type | 10-K |
| Filed Date | Mar 7, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, merger, financing, biotech
TL;DR
Allovir's 2024 10-K is in, showing a merger with Kalaris and some bridge financing. Big moves ahead.
AI Summary
Allovir, Inc. filed its 2024 10-K on March 7, 2025, reporting its fiscal year ending December 31, 2024. The company, formerly ViraCyte, Inc., is focused on biological products. Key events include a merger agreement with Kalaris Therapeutics, Inc. on November 7, 2024, and subsequent bridge financing on January 10, 2025.
Why It Matters
This filing provides a comprehensive overview of Allovir's financial health and strategic direction, including significant corporate actions like the merger with Kalaris Therapeutics.
Risk Assessment
Risk Level: medium — The company is in the biotechnology sector, which is inherently risky due to long development cycles and regulatory hurdles, compounded by recent merger activity.
Key Players & Entities
- Allovir, Inc. (company) — Filer of the 10-K
- ViraCyte, Inc. (company) — Former name of Allovir, Inc.
- Kalaris Therapeutics, Inc. (company) — Party in a merger agreement with Allovir
- 2024-12-31 (date) — Fiscal year end
- 2025-03-07 (date) — Filing date of the 10-K
- 2024-11-07 (date) — Date of merger agreement with Kalaris Therapeutics
- 2025-01-10 (date) — Date of subsequent bridge financing
FAQ
What is the primary business of Allovir, Inc.?
Allovir, Inc. is primarily involved in biological products, specifically classified under Biological Products (No Diagnostic Substances) [2836].
When did Allovir, Inc. file its 10-K report for the fiscal year ending December 31, 2024?
Allovir, Inc. filed its 10-K report on March 7, 2025.
What significant corporate event occurred on November 7, 2024, involving Allovir, Inc.?
On November 7, 2024, Allovir, Inc. entered into a merger agreement with Kalaris Therapeutics, Inc.
What type of financing did Allovir, Inc. secure on January 10, 2025?
On January 10, 2025, Allovir, Inc. secured additional permitted bridge financing.
What was Allovir, Inc.'s former company name?
Allovir, Inc.'s former company name was ViraCyte, Inc., with a date of name change on September 24, 2018.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 7, 2025 regarding Allovir, Inc. (KLRS).